MedTrace Logo

Effects of Hydrolysed Porcine Proteins on Muscle Protein Synthesis and Appetite

NCT02477410 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2017-01-11

No results posted yet for this study

Summary

The purpose of the study is to obtain a better understanding of how hydrolysed porcine proteins affect the human metabolism, including the effects on muscle protein synthesis, appetite and secretion of gastrointestinal hormones.

It is hypothesised that hydrolysed porcine proteins will stimulate muscle protein synthesis, affect appetite and the secretion of gastrointestinal hormones similar to hydrolysed whey protein.

Conditions

  • Hunger
  • Satiety Response
  • Protein Synthesis

Interventions

DIETARY_SUPPLEMENT

Hydrolysed porcine protein from blood

Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite

DIETARY_SUPPLEMENT

Hydrolysed porcine protein from muscle

Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite

DIETARY_SUPPLEMENT

Hydrolysed whey protein

Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite

Sponsors & Collaborators

  • Svineafgiftsfonden

    collaborator UNKNOWN

  • DC Ingredients

    collaborator UNKNOWN

  • Arla Food Ingredients Group P/S

    collaborator UNKNOWN

  • University of Copenhagen

    lead OTHER

Principal Investigators

  • Arne Astrup, DMSc · Department of Nutrition, Exercise and sports, University of Copenhagen

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2016-07-31
Completion
2016-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02477410 on ClinicalTrials.gov